(1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate | CAS:709031-45-8

We serve (1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate CAS:709031-45-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
(1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate

Chemical Name:(1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate
CAS.NO:709031-45-8
Synonyms:(1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate
(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxamide,methanesulfonic acid
2-Azabicyclo[3.1.0]hexane-3-carboxamide, (1S,3S,5S)-, methanesulfonate
 
Physical and Chemical Properties:
Molecular Formula C7H14N2O4S
Molecular Weight 222.262
 
Specification:
Appearance:Off-white to light brown powder
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Saxagliptin(CAS:361442-04-8).



Contact us for information like (1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Azabicyclo[3.1.0]hexane-3-carboxamide, (1S,3S,5S)-, methanesulfonate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxamide,methanesulfonic acid Use and application,2-Azabicyclo[3.1.0]hexane-3-carboxamide, (1S,3S,5S)-, methanesulfonate technical grade,usp/ep/jp grade.


Related News: It also said it would bar South Koreans from visiting China as tourists.1-Chloro-3-isocyanatobenzene manufacturer In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.N-([1,1'-biphenyl]-4-yl)-[1,1'-biphenyl]-2-amine supplier In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.(R)-Azepan-3-amine vendor In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.